Amgen and Allergan Report Results of ABP 798 (biosimilar, rituximab) in JASMINE Study for Non-Hodgkin’s Lymphoma

 Amgen and Allergan Report Results of ABP 798 (biosimilar, rituximab) in JASMINE Study for Non-Hodgkin’s Lymphoma

Amgen and Allergan Report Results of ABP 798 (biosimilar, rituximab) in JASMINE Study for Non-Hodgkin’s Lymphoma

Shots:

  • The JASMINE study involves assessing of ABP 798 vs its reference product, Rituximab at a dose of 375 mg/m2 (IV, qw) for 4wks. followed by dosing at weeks 12 and 20 in 256 patients with non-Hodgkin’s lymphoma
  • The JASMINE study results demonstrated bio-similarity data in its 1EPs i.e, ORR @28wks. and clinical equivalence to Rituxan. Additionally, the companies conducted a clinical study of ABP 798 in mod. to sev. RA patients resulting in clinical equivalence & pharmacokinetic similarity
  • ABP 798 is an anti-CD20 mAb having the same amino acid sequence as the reference product, Rituxan. In Dec 2011, Amgen and Allergan entered into a WW collaboration to develop & commercialize four oncology antibody biosimilar therapies

Click here to­ read full press release/ article | Ref: Amgen | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post